CRP and bacterial infectious disease: The primary aim of this study is to conduct a US economic evaluation of FebriDx, a novel, rapid point-of-care test that simultaneously measures two key infection biomarkers, C-reactive protein and Myxovirus resistance protein A (MxA) to accurately differentiate viral from bacterial infection.16,17